Simplicity Solutions LLC Buys Shares of 1,097 Insulet Co. (NASDAQ:PODD)

Simplicity Solutions LLC bought a new stake in shares of Insulet Co. (NASDAQ:PODD) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,097 shares of the medical instruments supplier’s stock, valued at approximately $238,000.

Other institutional investors have also added to or reduced their stakes in the company. Parkside Financial Bank & Trust increased its position in Insulet by 251.0% during the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 123 shares during the period. Allworth Financial LP grew its position in shares of Insulet by 104.5% in the 3rd quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 92 shares during the last quarter. Wolff Wiese Magana LLC grew its position in shares of Insulet by 2,680.0% in the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 134 shares during the last quarter. BluePath Capital Management LLC purchased a new position in shares of Insulet in the 3rd quarter worth approximately $31,000. Finally, First Manhattan Co. purchased a new position in shares of Insulet in the 4th quarter worth approximately $35,000.

Insulet Price Performance

Insulet stock opened at $166.25 on Friday. Insulet Co. has a 12-month low of $125.82 and a 12-month high of $335.91. The stock has a market cap of $11.64 billion, a P/E ratio of 57.13, a PEG ratio of 2.97 and a beta of 0.98. The company has a 50-day moving average price of $173.97 and a 200 day moving average price of $178.96. The company has a current ratio of 3.51, a quick ratio of 2.62 and a debt-to-equity ratio of 1.86.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The company had revenue of $509.80 million during the quarter, compared to analyst estimates of $461.26 million. During the same quarter last year, the firm posted $0.55 earnings per share. Insulet’s revenue was up 37.9% compared to the same quarter last year. Sell-side analysts anticipate that Insulet Co. will post 3.08 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Shacey Petrovic sold 11,609 shares of Insulet stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total value of $1,891,338.28. Following the completion of the transaction, the director now owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.90% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PODD. Piper Sandler cut their price objective on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Barclays cut their price objective on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research report on Monday, February 26th. JPMorgan Chase & Co. lifted their price objective on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Finally, Stifel Nicolaus lifted their target price on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research note on Monday, February 5th. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $243.21.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.